Sp372

DEFECATORY DISORDERS

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis. LIVE STREAM SESSION

Presenters

Speaker Image for Satish Rao
Medical College of Georgia
Speaker Image for Giuseppe Chiarioni
Speaker Image for Emma Carrington
Imperial College London

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for THE COLONIC BIOLOGICAL CLOCK AND PREDICTABILITY OF TIME OF BOWEL MOVEMENTS DURING TREATMENT WITH A VIBRATING CAPSULE (VIBRANT®) IN PATIENTS WITH SEVERE CHRONIC IDIOPATHIC CONSTIPATION
THE COLONIC BIOLOGICAL CLOCK AND PREDICTABILITY OF TIME OF BOWEL MOVEMENTS DURING TREATMENT WITH A VIBRATING CAPSULE (VIBRANT®) IN PATIENTS WITH SEVERE CHRONIC IDIOPATHIC CONSTIPATION
BACKGROUND: The gastrointestinal (GI) disturbance is a frequent complication in patients with thoracolumbar vertebral fracture (TVF), especially in the postoperative period. Laxatives are sometimes of limited effect…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…